|
43 Companies |
|
55 Products |
|
55 Products |
|
60 Mechanisms of Action |
|
1 Trial |
|
670 News |
|
| «12...234567891011121314» |
- Oxbryta (voxelotor) / Pfizer
New P1 trial: A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell Disease (clinicaltrials.gov) - Nov 6, 2014
P1, N=128, Not yet recruiting, Sponsor: Global Blood Therapeutics
- Trial primary completion date: Parent Willingness to Participate in Tobacco Trials in the Pediatric Clinical Setting (clinicaltrials.gov) - Nov 3, 2014
P=N/A, N=88, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Sep 2014 --> Dec 2014
- || Enrollment closed: The Feasibility of Text Messaging to Assess Secondhand Smoke Exposure Among Youngsters With Cancer or Sickle Cell Disease (clinicaltrials.gov) - Nov 3, 2014
P=N/A, N=110, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Sep 2014 --> Dec 2014 Recruiting --> Active, not recruiting
- Trial completion, Enrollment change: Microvascular and Cardiac Dysfunction in Paroxysmal Nocturnal Hemoglobinuria and Sickle Cell Disease (clinicaltrials.gov) - Oct 28, 2014
P=N/A, N=6, Completed, Sponsor: Oregon Health and Science University
Recruiting --> Active, not recruiting Recruiting --> Completed | N=70 --> 6
- SP-420 / AbFero
Enrollment open: Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia (clinicaltrials.gov) - Oct 28, 2014
P1, N=24, Recruiting, Sponsor: Sideris Pharmaceuticals
Recruiting --> Completed | N=70 --> 6 Not yet recruiting --> Recruiting
- SP-420 / AbFero
New P1 trial: Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia (clinicaltrials.gov) - Oct 24, 2014
P1, N=24, Not yet recruiting, Sponsor: Sideris Pharmaceuticals
- ||| Clinical: Families Taking Control (FTC): Family-based Problem-solving Intervention for Children With Sickle Cell Disease (clinicaltrials.gov) - Oct 23, 2014
P=N/A, N=83, Completed, Sponsor: University of Pennsylvania
- ||| Enrollment open: A New Reagent Assay Examining Natural Parvovirus B19 Infection in Sickle Cell Disease (clinicaltrials.gov) - Oct 22, 2014
P=N/A, N=89, Recruiting, Sponsor: St. Jude Children's Research Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment change, Trial withdrawal: CENTAurus: Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia (clinicaltrials.gov) - Oct 22, 2014
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting N=40 --> 0 | Not yet recruiting --> Withdrawn
- | hydroxyurea / Generic mfg.
Enrollment open, Trial initiation date: NOHARM: Novel Use Of Hydroxyurea in an African Region With Malaria (clinicaltrials.gov) - Oct 17, 2014
P3, N=200, Recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
N=40 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting | Initiation date: Jan 2014 --> Sep 2014
- Enrollment open: MEMREAD: Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease (clinicaltrials.gov) - Oct 2, 2014
P=N/A, N=99, Recruiting, Sponsor: St. Jude Children's Research Hospital
Not yet recruiting --> Recruiting | Initiation date: Jan 2014 --> Sep 2014 Not yet recruiting --> Recruiting
- | ticagrelor / Generic mfg.
Enrollment open, Enrollment change: HESTIA 1: A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease (clinicaltrials.gov) - Sep 28, 2014
P2, N=39, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | N=49 --> 39
- Enrollment open: Study of Beet Juice for Patients With Sickle Cell Anemia (clinicaltrials.gov) - Sep 22, 2014
P2, N=24, Recruiting, Sponsor: Daniel Kim-Shapiro
Not yet recruiting --> Recruiting | N=49 --> 39 Not yet recruiting --> Recruiting
- NKTT120 / NKT Therap
Enrollment closed, Trial primary completion date: Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD) (clinicaltrials.gov) - Sep 22, 2014
P1, N=21, Active, not recruiting, Sponsor: NKT Therapeutics
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Dec 2014
- Enrollment closed, Trial primary completion date: KNOW-IT: Improving Disease Knowledge in Adolescents With Sickle Cell Disease (clinicaltrials.gov) - Sep 12, 2014
P=N/A, N=150, Active, not recruiting, Sponsor: The University of The West Indies
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Dec 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Jan 2015
- | clindamycin phosphate / Generic mfg.
New P1 trial: Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ Challenge (clinicaltrials.gov) - Sep 11, 2014
P1, N=45, Recruiting, Sponsor: Sanaria Inc.
- || Clotinab (abciximab) / Isu Abxis
Trial primary completion date: Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis (clinicaltrials.gov) - Sep 4, 2014
P2, N=100, Recruiting, Sponsor: St. Louis University
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Jan 2015 Trial primary completion date: Nov 2015 --> Mar 2016
- | Jakafi (ruxolitinib) / Novartis, Incyte
Enrollment open, Trial primary completion date: Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia. (clinicaltrials.gov) - Sep 4, 2014
P2a, N=30, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Nov 2015 --> Mar 2016 Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2016 --> May 2016
- Clinical: Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease (clinicaltrials.gov) - Aug 29, 2014
P=N/A, N=99, Not yet recruiting, Sponsor: St. Jude Children's Research Hospital
- Trial completion, Enrollment change, Trial primary completion date: Beta-thalassemia and Microparticles (clinicaltrials.gov) - Aug 29, 2014
P=N/A, N=33, Completed, Sponsor: Assistance Publique Hopitaux De Marseille
Not yet recruiting --> Recruiting | Trial primary completion date: Feb 2016 --> May 2016 Recruiting --> Completed | N=55 --> 33 | Trial primary completion date: Mar 2013 --> Feb 2014
- Clinical: Fertility Preservation in Women Who Will Have Gonadotoxic Therapy or Hematopoetic Stem Cell Transplantation, and in Women With Sickle Cell Disease (clinicaltrials.gov) - Aug 26, 2014
P=N/A, N=10, Recruiting, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- | morphine sulphate / Generic mfg., hydromorphone hydrochloride / Generic mfg.
New P4 trial: Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease (clinicaltrials.gov) - Aug 21, 2014
P4, N=77, Not yet recruiting, Sponsor: Duke University
- Trial completion, Enrollment change: Cognitive Rehabilitation in Sickle Cell Disease (clinicaltrials.gov) - Aug 21, 2014
P=N/A, N=18, Completed, Sponsor: Duke University
Recruiting --> Completed | N=55 --> 33 | Trial primary completion date: Mar 2013 --> Feb 2014 Recruiting --> Completed | N=30 --> 18
- deferasirox tablet for oral suspension / Generic mfg.
Trial primary completion date: Post Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Aug 19, 2014
P4, N=30, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | N=30 --> 18 Trial primary completion date: Feb 2015 --> Oct 2015
- decitabine / Generic mfg.
Trial primary completion date: Decitabine for High-Risk Sickle Cell Disease (clinicaltrials.gov) - Aug 19, 2014
P2, N=40, Recruiting, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Trial primary completion date: Feb 2015 --> Oct 2015 Trial primary completion date: Dec 2016 --> Dec 2015
- Campath (alemtuzumab) / Sanofi
Trial completion, Trial primary completion date: Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders (clinicaltrials.gov) - Aug 15, 2014
P1, N=22, Completed, Sponsor: Duke University
Trial primary completion date: Dec 2016 --> Dec 2015 Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Dec 2012
- | ticagrelor / Generic mfg.
New P2 trial: HESTIA 1: A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease (clinicaltrials.gov) - Aug 12, 2014
P2, N=49, Not yet recruiting, Sponsor: AstraZeneca
- Mozobil (plerixafor) / Sanofi
New P1/2 trial: DrepaMob: Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients (clinicaltrials.gov) - Aug 8, 2014
P1/2, N=5, Not yet recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- hydroxyurea / Generic mfg.
Trial primary completion date: State Of The Art Functional Imaging In Sickle Cell Disease (clinicaltrials.gov) - Aug 7, 2014
P=N/A, N=60, Recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Dec 2012 Trial primary completion date: Dec 2014 --> Dec 2015
- Trial completion: Drépano: Systematic Psychological and Medical Care for Children With SCD (clinicaltrials.gov) - Aug 6, 2014
P=N/A, N=160, Completed, Sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Trial primary completion date: Dec 2014 --> Dec 2015 Recruiting --> Completed
- Enrollment open, Adherence: Medication Adherence in Youth With Sickle Cell Disease (SCD) (clinicaltrials.gov) - Aug 4, 2014
P=N/A, N=60, Recruiting, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Completed Not yet recruiting --> Recruiting
- propranolol / Generic mfg.
Trial completion, Trial primary completion date: Study of Propranolol as Anti-Adhesive Therapy in Sickle Cell Disease (SCD) (clinicaltrials.gov) - Aug 1, 2014
P2, N=27, Completed, Sponsor: Laura M. De Castro, MD
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Mar 2013 --> Dec 2013
- || Enrollment closed, Enrollment change, Trial primary completion date: SUFEMYO: Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations (clinicaltrials.gov) - Jul 28, 2014
P=N/A, N=110, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed | Trial primary completion date: Mar 2013 --> Dec 2013 Recruiting --> Active, not recruiting | N=210 --> 110 | Trial primary completion date: Mar 2014 --> Oct 2014
- Clinical: iTransition: Patient-Provider Tools to Improve the Transition to Adult Care in Sickle Cell Disease (clinicaltrials.gov) - Jul 27, 2014
P=N/A, N=85, Enrolling by invitation, Sponsor: Children's Hospital Medical Center, Cincinnati
- deferasirox tablet for oral suspension / Generic mfg., deferiprone / Generic mfg.
Combination therapy: Clinical Trial of Deferasirox Combination Treatment With Deferiprone In Thalassaemia Patients (clinicaltrials.gov) - Jul 23, 2014
P=N/A, N=13, Completed, Sponsor: China Medical University Hospital
- Trial termination: Inhaled Nitric Oxide for Pediatric Painful Sickle Crisis (clinicaltrials.gov) - Jul 23, 2014
P2, N=18, Terminated, Sponsor: Children's Hospital Boston
Recruiting --> Active, not recruiting | N=210 --> 110 | Trial primary completion date: Mar 2014 --> Oct 2014 Recruiting --> Terminated; 18 or 20 enrolled, stopped due to paucity of available participants
- Trial completion, MRI: MAFIO: MR Imaging of Diffuse Myocardial Fibrosis in Transfusion-Dependent Anemias (clinicaltrials.gov) - Jul 17, 2014
P=N/A, N=42, Completed, Sponsor: University Health Network, Toronto
Recruiting --> Terminated; 18 or 20 enrolled, stopped due to paucity of available participants Recruiting --> Completed
- | Trial completion: SIT: Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial (clinicaltrials.gov) - Jul 16, 2014
P3, N=196, Completed, Sponsor: Washington University School of Medicine
Recruiting --> Completed Active, not recruiting --> Completed
- Instanyl (fentanyl) / Takeda
Trial primary completion date: Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis (clinicaltrials.gov) - Jul 14, 2014
P4, N=200, Recruiting, Sponsor: Montefiore Medical Center
Active, not recruiting --> Completed Trial primary completion date: Sep 2014 --> Sep 2015
- deferiprone / Generic mfg.
Trial completion, Trial primary completion date: Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease (clinicaltrials.gov) - Jul 14, 2014
P1, N=8, Completed, Sponsor: ApoPharma
Trial primary completion date: Sep 2014 --> Sep 2015 Not yet recruiting --> Completed | Trial primary completion date: Jul 2013 --> Apr 2014
- Enrollment closed: The Brigance Assessment Of Individual Neurodevelopment In Young Children With Sickle Cell Disease- 2 (clinicaltrials.gov) - Jul 12, 2014
P=N/A, N=272, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Not yet recruiting --> Completed | Trial primary completion date: Jul 2013 --> Apr 2014 Recruiting --> Active, not recruiting
- budesonide inhalation suspension / Generic mfg.
New P1 trial: Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial (clinicaltrials.gov) - Jul 12, 2014
P1, N=20, Recruiting, Sponsor: Vanderbilt University
- Enrollment change: Adolescent, Caregiver, and Young Adult Perspectives of the Transition From Pediatric to Adult Care for Sickle Cell Disease: A Preliminary Evaluation of the Sickle Cell Disease Transition Program (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=55, Completed, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Active, not recruiting N=72 --> 55
- Trial completion, Enrollment change: Adolescent, Caregiver, and Young Adult Perspectives of the Transition From Pediatric to Adult Care for Sickle Cell Disease: A Preliminary Evaluation of the Sickle Cell Disease Transition Program (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=55, Completed, Sponsor: St. Jude Children's Research Hospital
N=72 --> 55 Recruiting --> Completed | N=72 --> 55
- Enrollment open: IMPROVE: Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease (clinicaltrials.gov) - Jun 19, 2014
P2, N=45, Recruiting, Sponsor: Jeffrey Glassberg
Recruiting --> Completed | N=72 --> 55 Not yet recruiting --> Recruiting
- Zyflo (zileuton) / Chiesi
Trial completion: Trial of Zileuton CR in Children and Adults With Sickle Cell Disease (clinicaltrials.gov) - Jun 19, 2014
P1, N=9, Completed, Sponsor: Children's Hospital Medical Center, Cincinnati
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- New P2 trial: Study of Beet Juice for Patients With Sickle Cell Anemia (clinicaltrials.gov) - Jun 13, 2014
P2, N=24, Not yet recruiting, Sponsor: Daniel Kim-Shapiro
- Trial primary completion date: CENTAurus: Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia (clinicaltrials.gov) - May 31, 2014
P4, N=40, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: Mar 2018 --> Dec 2018
- | Trial initiation date: CENTAurus: Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia (clinicaltrials.gov) - May 31, 2014
P4, N=40, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Mar 2018 --> Dec 2018 Initiation date: Mar 2014 --> Dec 2014
- Trial primary completion date: Carbon Monoxide Monitor for the Measurement of End-Tidal Carbon Monoxide Levels in Children With or Without Hemolysis (clinicaltrials.gov) - May 28, 2014
P=N/A, N=40, Completed, Sponsor: Ashutosh Lal
Initiation date: Mar 2014 --> Dec 2014 Trial primary completion date: Dec 2013 --> Mar 2014